Current disease status-First occurrence of the leukemia Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the leukemia Posts on Medivizor

Long-term effectiveness of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia

Posted by on Mar 16, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term safety and effectiveness of tyrosine kinase inhibitors for chronic-phase chronic myeloid leukemia. This study concluded that the outcomes for these patients are satisfactory and reliable. Some background Patients with chronic phase chronic myeloid leukemia (CP-CML) generally have mild...

Read More

Combining ibrutinib and umbralisib to treat relapsed/unresponsive chronic lymphocytic leukemia

Posted by on Feb 28, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib (Imbruvica) combined with umbralisib for patients with released/unresponsive chronic lymphocytic leukemia (CLL). This study concluded that the combination of umbralisib and ibrutinib is well tolerated and effective in relapsed/unresponsive CLL.  Some background...

Read More

Treatment of childhood ALL with therapy to the spinal area

Posted by on Feb 28, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the use of medication delivered to the spinal area (intrathecal) in patients with acute lymphoblastic leukemia (ALL). Researchers showed that this may be used instead of radiation to the head in these patients, with similar outcomes. Some background Acute lymphoblastic leukemia is a cancer of the immune system that...

Read More

Evaluating nilotinib with chemotherapy for acute lymphoblastic leukemia with abnormal genes

Posted by on Jan 31, 2019 in Leukemia | 0 comments

In a nutshell This study wanted to assess the safety and effectiveness of nilotinib (Tasigna) in the treatment of acute lymphoblastic leukemia (ALL) with abnormal genes. Researchers found that nilotinib was safe and effective in these patients when combined with chemotherapy. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the immune...

Read More

Evaluating long-term Intensive chemotherapy combined with ponatinib for ALL treatment

Posted by on Dec 29, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to assess the long-term safety and effectiveness of adding ponatinib (Iclusig) to intensive chemotherapy in the treatment of acute lymphoblastic leukemia. The study found that this treatment is effective on the long-term for these patients. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the bone...

Read More

Inotuzumab ozogamicin for children with unresponsive acute lymphoblastic leukemia

Posted by on Dec 21, 2018 in Leukemia | 0 comments

In a nutshell This study wanted to assess the safety and effectiveness of inotuzumab ozogamicin (InO; Besponsa) for the treatment of children with unresponsive acute lymphoblastic leukemia (ALL). Researchers found that InO was safe and effective in this group of patients. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the bone...

Read More

Is MRD related to treatment and survival in patients with chronic lymphocytic leukemia?

Posted by on Dec 12, 2018 in Leukemia | 0 comments

In a nutshell This study wanted to compare the effectiveness of chlorambucil (Leukeran) plus either obinutuzumab (Gazyva) or rituximab (Rituxan) in the treatment of frail patients with chronic lymphocytic leukemia (CLL). Researchers found that chlorambucil with obinutuzumab (G-Clb) was more effective than with rituximab (R-Clb) in these...

Read More

The effect of ibrutinib on white blood cell count in CLL

Posted by on Dec 6, 2018 in Leukemia | 0 comments

In a nutshell This study wanted to look at the effect of ibrutinib (Imbruvica) on white cell count (immune cells) in patients with chronic lymphocytic leukemia. Researchers found that increases in white cell count during ibrutinib treatment were normal and did not indicate poor outcomes in these patients. Some background Chronic lymphocytic leukemia...

Read More

Evaluating the safety and effectiveness of ponatinib for CML

Posted by on Dec 6, 2018 in Leukemia | 0 comments

In a nutshell The study looked at the safety and effectiveness of ponatinib (Iclusig) in the treatment of chronic myeloid leukemia (CML). Researchers found that ponatinib was safe and effective in previously treated patients with CML. Some background Chronic myeloid leukemia is a type of cancer of the bone marrow. This can lead to abnormal immune...

Read More